READ: ARW ON RNA
-
Picasso, Pick-Up Lines, & Personalized Medicine: mRNA's Path Forward
6/27/2025
Overall, my presentation on what the mRNA industry can learn from the artist Picasso singled out a few specific areas from which I felt our industry could garner greater inspiration and operational prowess. But given how “collaborative” many of these sources of inspiration are, I’ve introduced each of my takeaways with a surprisingly relevant (albeit bad) art-themed pick-up line. After all, if there’s one sector that knows it takes more than one to “tango,” it’s the mRNA industry.
-
Pictures At An [mRNA]Exhibition: What We Can Learn From Picasso (Pt. 1)
6/20/2025
In my presentation, I argued that there are three lessons we can learn from Picasso that will also help our own industry mature. In the upcoming weeks, I plan to unpack these lessons, highlighting specific instances in which I see our industry taking these lessons to heart and making progress — starting here with lesson 1: Being Innovative Comes After We Master The Basics
-
"Raiders Of The Lost Codon:" Alltrna On Evolving "Ancient" tRNA Into Therapeutics
5/6/2025
Here, in part one of this two-part article, we identify how tRNA stands apart from other RNA modalities and gene therapies, as well as how this molecule’s unique “skill set” is guiding the company’s future clinical strategy.
-
"Mirror, Mirror…": Reflections On Reducing mRNA Production COGS
4/21/2025
Here, I outline three overarching words of wisdom I gleaned from Life Edit Therapeutics’ April Sena; Tune Therapeutics’ Tyler Goodwin; and University of Sheffield’s Adi on how the mRNA/RNA industry can better control production costs — particularly as it relates to raw material sourcing and usage.
-
Plasmid Production: 3 Key Takeaways For mRNA Manufacturing
4/14/2025
Following my latest Live panel on analytical and manufacturing technology innovations for mRNA production, I wanted to provide a few high-level takeaways I gleaned from our discussion on the overlooked darling of the mRNA space: The plasmid.
-
Britney Spears' Take On Building Platform Analytics for mRNA Therapeutics
4/2/2025
As many of the presentations throughout the two-day USP quality forum revealed, we’re doing what we must to understand the benefits and the limitations of our methods. Yes, this is painstaking and expensive work. But understanding our methods is also one of the critical steps toward a future in which we can rely upon platform analytical procedures and — channeling our inner Britney Spears — say “[Ooo], I did it again!” to the regulatory agencies for each of the subsequent molecules in our pipelines.
-
Is The mRNA Payload The Real MVP of Targeted Delivery?
3/24/2025
As one delightfully colorful quote from a panel discussion at the AMM Ascent meeting last fall reminds us, there’s a lot more to be explored, discussed, and understood as it relates to the mRNA cargo’s role in targeted delivery.
-
Learning From Oligos: Delivery & Clinical Strategies For mRNA Therapeutics
3/17/2025
Those of us who attended the Alliance for mRNA Medicines’ inaugural Ascent conference last fall had the opportunity to hear from Zdravka Medarova of TransCode Therapeutics on her experiences working in the oligo sector. Here, I summarize some of her learnings and/or suggestions for the encoding RNA field as we set out to develop mRNA therapeutics for oncology.
-
The mRNA Industry's Three Wishes: Can CDMOs Play The "Genie?"
3/5/2025
During the panel discussion last November, three CDMO execs shared the biggest scientific, regulatory, and technological complexities barring a “magical” solution to each biotech’s wishes. However, as each of the AMM panelists pointed out, there are short- and long-term technological innovations in the works that will be essential in advancing the manufacturing infrastructure for mRNA therapeutics in all their shapes, forms, and scales.
-
Courtroom Clash: Inside The High-Stakes World Of mRNA Patent Litigation
2/28/2025
Here, Shores provides the “who’s who” and “what’s what” behind some of the hottest legal cases to hit the headlines in the mRNA space to-date, as well as why these cases are or could be significant to companies commercializing mRNA products in the future.